



## Covid-19 Monoclonal Antibody Selection Criteria

### Criteria for Use:

This EUA is for the use of Covid-19 Monoclonal Antibody for the prophylaxis and treatment of mild to moderate COVID19 in adults and pediatric patients with exposure and/or positive results SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kg, and who are at the highest risk for progressing to severe COVID-19 and/or hospitalization.

---

- Covid-19 Monoclonal Antibody should be administered as soon as possible after symptom onset AND a positive viral test for SARS-CoV2 AND must be within 10 days of symptom onset.
- 

Due to a national shortage of monoclonal antibody, Tulsa ER & Hospital is reserving the use of Sotrovimab for only those patients meeting the highest risk factors as outlined below:

1. Patient is a transplant patient on “anti-rejection” medication

OR

2. Patient has **at least 3 or more** of the following High-Risk criteria:

- |   |  |
|---|--|
| <input type="checkbox"/> Body mass index (BMI) >30              | <input type="checkbox"/> Cardiovascular Disease/HTN  |
| <input type="checkbox"/> Age $\geq$ 65 years                    | <input type="checkbox"/> Chronic respiratory disease |
| <input type="checkbox"/> Chronic kidney disease                 | <input type="checkbox"/> Pregnancy                   |
| <input type="checkbox"/> Diabetes                               | <input type="checkbox"/> Neurodevelopmental disorder |
| <input type="checkbox"/> Immunosuppressive disease or currently | <input type="checkbox"/> Sickle Cell Disease         |
| <input type="checkbox"/> receiving immunosuppressive treatment  |  |

3. Are 12 – 17 years of age AND >40kg

- BMI  $\geq$ 85th percentile for their age and gender based on CDC growth charts and
- 2 or more of the above criteria or
- Medical-related technological dependence